Bristol Myers' ( BMY ) Breyanzi Label Expansion Application Validated
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
| Ticker |
Sentiment |
Impact |
|
KRYS
|
Neutral
|
22 %
|
|
TSVT
|
Neutral
|
11 %
|
|
GILD
|
Somewhat Bullish
|
6 %
|
|
BMY
|
Somewhat Bullish
|
38 %
|
|
JNJ
|
Somewhat Bullish
|
6 %
|
